Unapproved fat-dissolving products sold online
This article was originally published in The Tan Sheet
Executive Summary
FDA sent warning letters to U.S. health spas and a Brazil-based online retailer, which operates the Web sites zipmed.net and mesoone.com, about unapproved "lipodissolve" products and procedures. Lipodissolve involves drug injections intended to dissolve and permanently remove pockets of fat. The most commonly injected substances are the lecithin phosphatidylcholine and the bile acid dioxycholate, usually together and combined with vitamins, minerals and herbal extracts. A third substance that is an approved drug to treat respiratory problems in premature infants, Forest's Infasurf (calfactant), also has been found in lipodissolve formulations, according to FDA. The agency has received reports of permanent scarring, hard lumps and dark spots on consumers' skin after lipodissolve treatments. While FDA sent a warning letter about lipodissolve to only one Web retailer, more sites likely sell the products directly to consumers, Kathleen Anderson, deputy director in the Center for Drug Evaluation and Research's Division of New Drugs and Labeling Compliance, said during an April 6 conference call
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.